Table 2.
Clinical trials: Registered MSC-based treatment in ARDS
| Identifier (status) | Disease | Phase | Cell source | Dosage | Route | Enrolled number | Primary outcomes |
|---|---|---|---|---|---|---|---|
| NCT01775774 (Completed) | ARDS | 1 | BM-MSCs | 1, 5, 10 × 106 cells/kg | I.V | 9 | Infusion associated adverse events |
| NCT02097641 (Completed) | ARDS | 2a | BM-MSCs | 1 × 107 cells/kg | I.V | 60 | Infusion associated adverse events, numbers of death within 24 h |
| NCT01902082 (Unknown) | ARDS | 1 | AD-MSCs | 1 × 106 cells/kg | I.V | 20 | Adverse events |
| NCT02804945 (Completed) | ARDS in patients with malignancies | 1 | BM-MSCs | 3 × 106 cells/kg | I.V | 20 | Adverse events |
| ChiCTR2000029990 (Recruiting) | Covid-19-related pneumonitis | 1–2 | BM-MSCs | 1 × 106 cells/kg | I.V | 60 | Blood oxygen saturation |
| NCT04355728 (Recruiting) | Covid-19 patients | 1–2 | UC-MSCs |
1 × 108 cells (2 times) |
I.V | 24 | Adverse events |
| NCT03042143 (Recruiting) | Covid-19-related ARDS | 1–2 | UC-MSCs | 1, 2, 4 × 108 cells | I.V | 75 | Oxygenation index, adverse events |
| NCT04390139 (Recruiting) | Covid-19-related respiratory distress | 1–2 | WJ-MSCs | 1 × 106 cells/kg | I.V | 30 | All-cause mortality at day 28 |
| NCT02095444 (Recruiting) | H7N9-related ARDS | 1–2 | MB-MSCs | 1 × 107 cells/kg (4 times) | I.V | 20 | The degree of lung injury within 14 days |
| NCT04416139 (Recruiting) | Covid-19-related ARDS | 2 | UC-MSCs | 1 × 106 cells/kg | I.V | 10 | PaO2/FiO2 ratio, heart rate, respiratory rate, changes in body temperature |
| NCT04366063 (Recruiting) | Covid-19-related ARDS | 2–3 | BM-MSCs | 1 × 108 cells (2 times) | I.V | 60 | Adverse events, blood oxygen saturation |
| NCT04371393 (Recruiting) | Covid-19-related ARDS | 3 | BM-MSCs | 2 × 106 cells/kg (2 times) | I.V | 300 | All-cause mortality at day 30 |
AD-MSCs adipose-derived mesenchymal stem cells, BM-MSCs bone marrow-derived mesenchymal stem cells, I.V. intravenous, MB-MSCs menstrual blood-derived mesenchymal stem cells, UC-MSCs umbilical cord-derived mesenchymal stem cells, WJ-MSCs Wharton-Jelly mesenchymal stromal cells